Norris Medicines Ltd

AGM Details

• AGM held on 29 September 2026, 2:30 PM to 2:45 PM, via VC/OAVM.
• Record date 22 September 2026; total shareholders on record: 25,799.
• Meeting category: Ordinary and Special business; 6 resolutions considered.

Resolutions and outcomes

• Resolution 1 (Ordinary) passed: Adoption of Audited Financial Statements for year ended 31 March 2026.
• Resolution 2 passed: Appointment of Praveen F. Bafna as director by rotation.
• Resolution 3 (Special) passed: Appointment of Vimal D. Shah as Managing Director; MD vote noted invalid for result.
• Resolution 4 passed: Increase in limits of borrowing.
• Resolution 5 passed: Authorization for sale, lease, or disposal of the whole undertaking.
• Resolution 6 passed: Enhancement of the existing limit under Section 186.

AGM Details

• Date and mode: 29 September 2026, VC/OAVM.
• Meeting time: 2:30 PM to 2:45 PM.
• Attendance: 40 members present.
• Voting rights cutoff: 22 September 2026.
• Remote e-voting window: 26-28 September 2026.
• E-voting agent: Purva Sharegistry India Private Limited.

Resolutions proposed

• Ordinary: adoption of Audited Financial Statements and Reports.
• Ordinary: re-appoint a director by rotation.
• Special: appointment of MD.
• Special: increase in borrowing limits.
• Special: authorize sale, lease, or disposal of undertakings.
• Special: enhance limits under Section 186.

Voting status

• Voting results will be announced within two working days and posted on the company site.

Norris Medicines Ltd: Trading Window closed from 1 October 2026 for designated persons (including promoters, directors, auditors, KMPs and their immediate relatives); will reopen 48 hours after declaration of unaudited financial results for the quarter ending 30 September 2026.

Board and AGM actions

• Approved Directors Report and 35th Annual Report including AGM notice for FY2025-26.
• Approved closure of Register of Members and share transfer books for AGM.
• Approved cut-off date for electronic voting entitlement.
• Approved 35th AGM on 29 September 2026 via VC/OAVM.
• Authorized Directors/Company Secretary to conduct AGM and issue the Notice.
• Appointed Scrutinizer for AGM e-voting: Hemant Shetye; fallback to Kunal Sakpal.
• Approved Purva Sharegistry (India) Pvt. Ltd. as EVoting facilitator.
• Authorized to sign and dispatch AGM notice and related documents.

Board actions

• Un-audited results for quarter ended June 30, 2026 approved with Limited Review Report.
• Vimal Dhirendra Shah appointed Managing Director for 3 years from Sep 1, 2026, subject to shareholder approval.

Meeting Details

• Date: Friday, 14th August 2026; Venue: Registered office, Plot No.801/P, GIDC, Ankleshwar, Gujarat 393002

Key Agenda Items

• Consider and approve unaudited quarterly results for quarter ended 30 June 2026, with Limited Review Report.
• Any other business with permission of Chair.

Other Notes

• Trading window closed from July 1, 2026 until 48 hours after Q1 results declaration.

CFO Appointment

• Type of change: Appointment of CFO and KMP.
• Person: Mr. Iqubal Ismail Patel appointed as Chief Financial Officer.
• Effective date: 30 July 2026.
• Term: On terms including remuneration mutually agreed.
• Profile: 11+ years with Norris Medicines; finance, budgeting, taxation, corporate management.
• Relationship: Not related to Directors or KMP.
• Board/Committee impact: Approved by Audit Committee and Nomination & Remuneration Committees.
• Reason: Appointment as Chief Financial Officer.

Reg 74(5) dematerialisation update

• Compliance certificate confirms dematerialisation for quarter ended June 2026 under Reg 74(5).
• Purva Sharegistry confirms processing and listing on exchanges for dematerialised securities.
• Dematerialisation certificates confirmed or rejected; register of members updated within prescribed timelines.
• RTA provides dematerialised holding details, including shareholder names and demat dates.